Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-002200

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
James Patrick Kelly
Officer — SVP, CFO & Treasurer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jan 3, 2017M2,344—A63,116D
Common StockF1Jan 3, 2017M5,000—A68,116D
Common StockF1Jan 3, 2017M5,000—A73,116D
Common StockF1Jan 3, 2017M7,500—A80,616D
Common StockF3Jan 3, 2017S10,895$15.5129D69,721D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitF1,F4,F5—Jan 3, 2017M2,344A——Common Stock2,3440D
Restricted Stock UnitF1,F6,F5—Jan 3, 2017M5,000A——Common Stock5,0005,000D
Restricted Stock UnitF1,F7,F5—Jan 3, 2017M5,000A——Common Stock5,00010,000D
Restricted Stock UnitF1,F8,F5—Jan 3, 2017M7,500A——Common Stock7,50022,500D

Explanation of responses